Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002–14.

Article  CAS  PubMed  Google Scholar 

Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852–63.

Article  CAS  PubMed  Google Scholar 

Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67.

Article  CAS  PubMed  Google Scholar 

O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614–27.

Article  PubMed  Google Scholar 

Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162:5813–20.

Article  CAS  PubMed  Google Scholar 

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6.

Article  CAS  PubMed  Google Scholar 

Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi A, Namikawa K, Ogata D, Nakano E, Jinnai S, Nakama K, et al. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. J Dermatol. 2020;47:1267–75.

Article  CAS  PubMed  Google Scholar 

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19:3977–86.

Article  CAS  PubMed  Google Scholar 

Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci USA. 2016;113:E2383–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kurtz J, Raval F, Vallot C, Der J, Sykes M. CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood. 2009;113:3475–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Chen S, Lan P, Wu C, Dou Y, Xiao X, et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model. Am J Transpl. 2018;18:604–16.

Article  CAS  Google Scholar 

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–43.

Article  CAS  PubMed  Google Scholar 

Kerdiles YM, Stone EL, Beisner DR, McGargill MA, Ch’en IL, Stockmann C, et al. Foxo transcription factors control regulatory T cell development and function. Immunity. 2010;33:890–904.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC, et al. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007;179:3831–40.

Article  CAS  PubMed  Google Scholar 

Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem. 2006;281:36828–34.

Article  CAS  PubMed  Google Scholar 

Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349:436–40.

Article  CAS  PubMed  Google Scholar 

Walsh MC, Lee J, Choi Y. Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system. Immunol Rev. 2015;266:72–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460:103–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cejas PJ, Walsh MC, Pearce EL, Han D, Harms GM, Artis D, et al. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood. 2010;115:4750–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilcox RA. A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol. 2016;91:113–22.

Article  CAS  PubMed  Google Scholar 

Xiao X, Balasubramanian S, Liu W, Chu X, Wang H, Taparowsky EJ, et al. OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol. 2012;13:981–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bidère N, Snow AL, Sakai K, Zheng L, Lenardo MJ. Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation. Curr Biol. 2006;16:1666–71.

Article  PubMed  Google Scholar 

Deng T, Hu B, Wang X, Ding S, Lin L, Yan Y, et al. TRAF6 autophagic degradation by avibirnavirus VP3 inhibits antiviral innate immunity via blocking NFKB/NF-kappaB activation. Autophagy. 2022;18:2781–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med. 2006;12:1088–92.

Article  CAS  PubMed  Google Scholar 

Xiao X, Fan Y, Li J, Zhang X, Lou X, Dou Y, et al. Guidance of super-enhancers in regulation of IL-9 induction and airway inflammation. J Exp Med. 2018;215:559–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu Y, Wang Q, Xue G, Bi E, Ma X, Wang A, et al. Th9 cells represent a unique subset of CD4(+) T cells endowed with the ability to eradicate advanced tumors. Cancer Cell. 2018;33:1048–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Q, Huang H, Zhang L, Wu R, Chung CI, Zhang SQ, et al. Visualizing dynamics of cell signaling in vivo with a phase separation-based kinase reporter. Mol Cell. 2018;69:334–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang D, Xing Q, Su Y, Zhao X, Xu W, Wang X, et al. The conserved non-coding sequences CNS6 and CNS9 control cytokine-induced Rorc transcription during T helper 17 cell differentiation. Immunity. 2020;53:614–26.

Article  CAS  PubMed  Google Scholar 

Wu J, Zhang H, Shi X, Xiao X, Fan Y, Minze LJ, et al. Ablation of transcription factor IRF4 promotes transplant acceptance by driving allogenic CD4(+) T cell dysfunction. Immunity. 2017;47:1114–28.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui J, Yu J, Xu H, Zou Y, Zhang H, Chen S, et al. Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation. Theranostics. 2020;10:8051–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 2019;29:609–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi YB, Harhaj EW. HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation. PLoS Pathog. 2014;10:e1004458.